Erich Mounce, chief operating officer, OneOncology, discusses how payment models like the Oncology Care Model are changing the way oncologists practice, as well as what practices should prioritize when looking to participate in a payment model.
Erich Mounce, chief operating officer, OneOncology, discusses how payment models like the Oncology Care Model are changing the way oncologists practice, as well as what practices should prioritize when looking to participate in a payment model.
Transcript
How are payment models, such as the Oncology Care Model, changing the way community oncologists practice?
I think for the better. From my perspective, that standardization of payment models is allowing us to drive the same kind of care based on evidence. For example, it send to be that medical oncologists could only use 1 or 2 drugs in their tool chest. Not all of those drugs would work on those cancers, but they’d use them anyway because there was a 50/50 chance or a 60/40 chance that they would work. Now, with targeted medicine, that allows us to target the right drugs and then allows us to really work on value-based care, Oncology Care Model standardization to use a care model that processes through with the patient’s care.
It’s not just a regimen. For us at OneOncology, a care pathway or a care model that goes within a bundled payment or Oncology Payment Model is also really soup to nuts. It is, once you’re diagnosed, when do you see a genetic counselor? When do you see the surgeon? When do you get the CT [computerized tomography] scan? When do you get the PET [positron emission tomography] scan? When do you have surgery? When do you have chemo? It’s not just what drugs are used, and for me, that’s really a challenging step that gives a lot of opportunity to be successful with patient care in the future.
When looking to participate in a payment model, what should practices prioritize?
There’s lots of variations out there. The most important thing is to find a model that’s passionate about patient care and about the delivery of that care, not just commoditizing drug prices or supply prices. It’s really about making sure you have somebody that believes the same way that a physician did when they went to school and now that they’re a medical oncologist about how to treat the patient right and everything else follows that.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More